Personalized Gastrointestinal Tract Disease Treatment System

A next-generation, ingestible device-based system for treating gastrointestinal tract diseases, leveraging autonomous sensing, real-time data analytics, and targeted JAK inhibitor delivery to provide personalized, adaptive treatment plans.

The original patent disclosed methods and compositions for treating diseases of the gastrointestinal tract with JAK inhibitors. However, these approaches are limited by their lack of precision, potential systemic side effects, and inability to adapt to individual patient needs. The new inventive concept addresses these limitations by introducing an ingestible device that can detect disease biomarkers, generate customized treatment plans, and release pharmaceutical formulations comprising JAK inhibitors at specific locations in the GI tract.

The system consists of an ingestible device with a sensor module for detecting disease biomarkers, a treatment module for releasing pharmaceutical formulations comprising JAK inhibitors, and a communication module for transmitting treatment data to a remote server. The device can sample the GI tract, detect disease biomarkers, and release the formulation at a location proximate to the detected disease site. The system also includes a data analytics module that analyzes disease progression and adjusts the treatment plan in real-time. The method for personalized treatment involves detecting disease biomarkers, generating a customized treatment plan, and administering the pharmaceutical formulation according to the plan.

The new claims introduce the concept of autonomous, real-time sensing and adaptive treatment planning, which is not present in the original patent. The use of ingestible devices, data analytics, and targeted JAK inhibitor delivery provides a paradigm shift in the treatment of gastrointestinal tract diseases, offering a more precise, effective, and patient-centric approach.

Alternative embodiments may include variations in the design and functionality of the ingestible device, such as different sensor modalities, treatment modules, or communication protocols. Other variations may involve the use of different types of pharmaceutical formulations or JAK inhibitors, or the integration of additional features, such as artificial intelligence or machine learning algorithms, to enhance the system's performance and adaptability.

The personalized gastrointestinal tract disease treatment system has significant commercial potential in the pharmaceutical and medical device industries, with potential applications in the treatment of various GI tract diseases, such as Crohn's disease, ulcerative colitis, and irritable bowel syndrome. The system's adaptability, precision, and patient-centric approach may also lead to increased adoption and market share in the growing digital health and personalized medicine markets.